Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison

키워드

참고문헌 (53)

1. Malaspina D., "Schizophrenia: a neurodevelopmental or a neurodegenerative disorder", J Clin Psychiatry, 67, pp.e07~ (2006)
2. Knapp M., "The global costs of schizophrenia", Schizophr Bull, 30, pp.279~293 (2004)
3. Byrne P., "Managing the acute psychotic episode", BMJ, 334, pp.686~692 (2007)
4. Lieberman JA., "Factors influencing treatment response and outcome of first-episode schizophrenia : implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry", 57 Suppl, 9, pp.5~9 (1996)
5. Huber CG., "Incomplete remission and treatment resistance in first-episode psychosis : definition, prevalence and predictors", Expert Opin Pharmacother, 9, pp.2027~2038 (2008)
6. Webb T., "Antipsychotic treatment of first-episode or early-onset schizophrenia", Curr Psychiatry Rep, 11, pp.261~263 (2009)
7. Moore TA., "The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia : 2006 update", J Clin Psychiatry, 68, pp.1751~1762 (2007)
8. Falkai P., "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of schizophrenia, Part 1 : acute treatment of schizophrenia", World J Biol Psychiatry, 6, pp.132~191 (2005)
9. Lehman AF., "Practice guideline for the treatment of patients with schizophrenia, second edition", Am J Psychiatry, 161(2 Suppl), pp.1~56 (2004)
10. Yang M., "Antipsychotic medication utilization trends among Texas veterans : 1997-2002", Ann Pharmacother, 42, pp.1229~1238 (2008)
11. Gallego JA., "Prevalence and correlates of antipsychotic polypharmacy : a systematic review and meta-regression of global and regional trends from the 1970s to 2009", Schizophr Res, 138, pp.18~28 (2012)
12. Barnes TR., "Evidence-based guidelines for the pharmacological treatment of schizophrenia : recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 25, pp.567~620 (2011)
13. Salimi K., "Antipsychotic drugs for first-episode schizophrenia : a comparative review", CNS Drugs, 23, pp.837~855 (2009)
14. Barbui C., "Factors associated with antipsychotic dosing in psychiatric inpatients : a prospective study", Int Clin Psychopharmacol, 22, pp.221~225 (2007)
15. Sernyak MJ., "Clinicians' reasons for deviations from recommended dosing practices for antipsychotic medications", Adm Policy Ment Health, 34, pp.540~547 (2007)
16. Procyshyn RM., "Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting : a review of medication profiles in 435 Canadian outpatients", J Clin Psychiatry, 71, pp.566~573 (2010)
17. Barbui C., "Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries", Int Clin Psychopharmacol, 21, pp.355~362 (2006)
18. American Psychiatric Association., "Diagnostic and statistical manual of mental disorders : DSM-IV. 4th ed" (1994), American Psychiatric Association
19. WHO Collaborating Centre for Drug Statistics Methodology., "Guidelines for ATC classification and DDD assignment. 5th ed" (2002), WHO Collaborating Centre for Drug Statistics Methodology
20. Consensus statement on high dose antipsychotic medication, "Royal College of Psychiatrists.", Royal College of Psychiatrists, ~, pp.Council Report CR138 (2006)
21. Nielsen J., "10-year trends in the treatment and outcomes of patients with first-episode schizophrenia", Acta Psychiatr Scand, 122, pp.356~366 (2010)
22. Leucht S., "Evidence-based pharmacotherapy of schizophrenia", Int J Neuropsychopharmacol, 14, pp.269~284 (2011)
23. Kinon BJ., "Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder : a randomized, double-blind, fixed-dose study", J Clin Psychopharmacol, 28, pp.392~400 (2008)
24. Takahashi H., "Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia : an open trial", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1067~1072 (2006)
25. Schwartz TL., "Treatment strategies for dosing the second generation antipsychotics", CNS Neurosci Ther, 17, pp.110~117 (2011)
26. Agid O., "Antipsychotic response in first-episode schizophrenia : efficacy of high doses and switching", Eur Neuropsychopharmacol, 23, pp.1017~1022 (2013)
27. Lass J., "Pharmacotherapy of first episode psychosis in Estonia : comparison with national and international treatment guidelines", J Clin Pharm Ther, 33, pp.165~173 (2008)
28. Wu CS., "Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006", Pharmacoepidemiol Drug Saf, 21, pp.989~996 (2012)
29. Zhang JP., "Efficacy and safety of individual secondgeneration vs. first-generation antipsychotics in first-episode psychosis : a systematic review and meta-analysis", Int J Neuropsychopharmacol, 16, pp.1205~1218 (2013)
30. Freudenreich O., "Optimizing outcome with antipsychotic treatment in first-episode schizophrenia : balancing efficacy and side effects", Clin Schizophr Relat Psychoses, 6, pp.115~121 (2012)
31. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care, "National Institute for Clinical Excellence.", National Institute for Clinical Excellence, ~, pp.NICE Clinical guideline 82 (2009)
32. Crossley NA., "Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis : meta-analysis", Br J Psychiatry, 196, pp.434~439 (2010)
33. Abdel-Baki A., "Pharmacotherapy challenges in patients with first-episode psychosis", J Affect Disord, 138(Suppl), pp.S3~S14 (2012)
34. Newcomer JW., "Metabolic considerations in the use of antipsychotic medications: a review of recent evidence", J Clin Psychiatry, 68(Suppl 1), pp.20~27 (2007)
35. Rummel-Kluge C., "Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia : a systematic review and meta-analysis", Schizophr Res, 123, pp.225~233 (2010)
36. Buchanan RW., "The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements", Schizophr Bull, 36, pp.71~93 (2010)
37. Correll CU., "Antipsychotic polypharmacy : a survey study of prescriber attitudes, knowledge and behavior", Schizophr Res, 131, pp.58~62 (2011)
38. López de Torre A., "Antipsychotic polypharmacy : a needle in a haystack?", Gen Hosp Psychiatry, 34, pp.423~432 (2012)
39. Gugger JJ., "Low-dose quetiapine is not a benign sedative-hypnotic agent", Am J Addict, 17, pp.454~455 (2008)
40. Zhornitsky S., "Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders : a systematic review of the placebo-controlled monotherapy and add-on trials", Int Clin Psychopharmacol, 26, pp.183~192 (2011)
41. Verdoux H., "Pharmaco-epidemiology : what do(and don't)we know about utilisation and impact of psychotropic medications in real-life conditions?", Br J Psychiatry, 185, pp.93~94 (2004)
42. Leucht S., "A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia", Am J Psychiatry, 166, pp.152~163 (2009)
43. Tandon R., "World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia", Schizophr Res, 100, pp.20~38 (2008)
44. Wang PS., "Should clozapine continue to be restricted to third-line status for schizophrenia? : a decision-analytic model", J Ment Health Policy Econ, 7, pp.77~85 (2004)
45. Honigfeld G., "Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry", J Clin Psychiatry, 59(Suppl 3), pp.3~7 (1998)
46. Munro J., "Active monitoring of 12, 760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance", Br J Psychiatry, 175, pp.576~580 (1999)
47. Tiihonen J., "11-year follow-up of mortality in patients with schizophrenia : a population-based cohort study(FIN11 study)", Lancet, 374, pp.620~627 (2009)
48. Lieberman JA., "Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia : a 52-week randomized trial of clozapine vs chlorpromazine", Neuropsychopharmacology, 28, pp.995~1003 (2003)
49. Sanz-Fuentenebro J., "Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia : results after one year", Schizophr Res, 149, pp.156~161 (2013)
50. Rebecca Schennach, "Treatment Response in First-episode Schizophrenia", Clinical Psychopharmacology and Neuroscience, 10(2), pp.78~87 (2012), 대한정신약물학회[DOI]
51. Siris SG., "Depression in schizophrenia : perspective in the era of"Atypical"antipsychotic agents", Am J Psychiatry, 157, pp.1379~1389 (2000)
52. Weiden PJ., "Expert consensus treatment guidelines for schizophrenia: A guide for patients and families", J Clin Psychiatry, 60(Suppl 11), pp.73~80 (1999)
53. Rijcken CA., "Chlorpromazine equivalents versus defined daily doses : how to compare antipsychotic drug doses?", J Clin Psychopharmacol, 23, pp.657~659 (2003)

관련 논문AI추천